NRO-1 is a topically delivered, nerve regenerative therapeutic that accelerates nerve regeneration and recovery of functional nerves
Corneal Nerve Degeneration
Retinal Ganglion Cell Degeneration
NRO-1 releases glial cell-derived neurotrophic factor (GDNF), which recovers ocular surface function through regenerating corneal nerves and accelerating corneal wound healing directly
Based on the results from the Phase 1 SAD and MAD clinical studies, a Phase 2 clinical study of NRO-1 in dry eye disease was initiated in the January 2020.
NRO-1 has shown efficacy in a range of nonclinical studies
Nerve damage is linked to a range of ophthalmic diseases, including dry eye disease, creating a high probability of success for human studies
Multicenter, randomized, double-asked, vehicle-controlled clinical trial that will evaluate the safety and efficacy of NRO-1in patients with dry eyed disease
120 patients with moderate-to-severe drye disease, including post-surgical patients.
2 dosages of NRO-1 compared to
Study initiated in Janary 2020, with results available in 2H 2020
Similar safety and tolerability to placebo
No serious or severe adverse events
No clinical chemistry, hematology or ECG safety concerns
Safety profile consistent with preclinical data and supportive of continuing to Phase 2